In vitro study demonstrates an 18-fold increase in transdermal metoclopramide permeation using hydrogel microneedles, indicating a viable alternative for managing nausea.
Key Points
To design and optimize biocompatible hydrogel microneedles composed of Gantrez S-97 and hyaluronic acid for sustained transdermal delivery of metoclopramide.
Fabricated hydrogel microneedle matrices by crosslinking Gantrez S-97 with sodium hyaluronate at 80 °C and incorporating polyvinyl pyrrolidone to improve stability.
Loaded metoclopramide hydrochloride across varying polymer ratios and evaluated needle morphology, mechanical strength, and in vitro transdermal drug permeation.
Optimized formulations exhibited uniform needle morphology and sufficient mechanical strength to penetrate the skin barrier.
The hydrogel microneedle system provided sustained release of metoclopramide across a 24-hour testing period.
Microneedle delivery produced up to an 18-fold enhancement in drug permeation compared to a standard transdermal film formulation.